Two stocks from entirely different sectors of ASX listed companies are indicating growth potential in the upcoming year. The stocks of potential growth companies are
Artrya Limited (ASX: AYA)
Artrya Limited (ASX: AYA) has made significant strides towards commercializing its Salix software, focusing on the U.S. market while expanding its footprint in Australia. Over the past year, the company prioritized re-engaging with the FDA to secure necessary approvals and preparing for entry into the U.S. healthcare system. In June 2023, Artrya, among the best growth stocks to buy now, held a Q-Sub meeting with the FDA, where a roadmap was agreed upon to support its regulatory journey. The company has since submitted a 510(k) application for its Salix Coronary Anatomy (SCA) product, with clearance expected in the first half of 2025. Strategic partnerships with three prominent U.S. hospital groups, representing over 15,000 CCTA scans annually, have been established to test the software and streamline its integration into clinical workflows. AYA is among the top growth stocks as it sets the stage for revenue generation post-FDA clearance.
On the commercial front, Artrya's software has been generating revenue in Australia, notably through a partnership with The Cardiac Centre in NSW. The company is in advanced talks with major Australian radiology groups, which could lead to broader adoption across the country. In parallel, Artrya is gaining significant interest in the U.S., where the adoption of Coronary Computed Tomography Angiography (CCTA) is growing rapidly, bolstered by recent reimbursement increases from Medicare. The company is poised to leverage this favorable reimbursement environment, which provides a clear financial incentive for hospitals and clinicians to adopt AI-assisted CCTA analysis. Artrya's cloud-based, point-of-care approach offers a competitive advantage, with faster and more efficient reporting compared to traditional methods.
For 2025, Artrya's key priorities include obtaining FDA approvals for Salix Coronary Plaque and Salix Coronary Flow, expanding its U.S. client base, and driving revenue growth through both U.S. and Australian markets. With a solid foundation in place, including the completion of a successful $5 million capital raise to extend its financial runway, Artrya is well-positioned for continued growth. Its focus remains on securing U.S. market access, further validating its product, and driving commercialization to take full advantage of the burgeoning AI-assisted CCTA market.
Nova Minerals limited (ASX: NVA)
Nova Minerals limited (ASX: NVA) has delivered impressive results from its Stibium Antimony-Gold prospect, confirming the area as a high-value exploration target. Announced on December 11, 2024, recent rock chip sampling revealed exceptional gold grades of up to 141 g/t Au and notable antimony concentrations, with earlier assays showing up to 60.5%. Spanning an 800m by 400m zone, Stibium presents significant exploration potential and is poised to be a prime drilling candidate for 2025, supported by favourable market conditions for both gold and antimony. The Estelle Gold and Critical Minerals Project in Alaska is rapidly becoming one of North America’s most promising mining districts. Covering 514km² with a 35km-long mineralized corridor, the project benefits from Alaska’s supportive regulatory environment and proximity to essential infrastructure, including the proposed West Susitna Access Road. Nova is exploring innovative power solutions, such as micro-nuclear reactors and grid connectivity, to enhance the project’s long-term viability. The RPM zone within Estelle continues to shine, with 2024 drilling revealing over 20 significant intercepts exceeding 5 g/t Au, including a peak grade of 52.7 g/t Au. Importantly, all drill holes ended in mineralization, highlighting the potential for resource expansion and positioning RPM as a key component of a future starter mine.
Less than 5% of the Estelle property has been explored, leaving substantial upside across other targets like Korbel, Muddy Creek, and Stoney. Korbel offers a large-scale, low-strip-ratio gold deposit with high-grade potential at Cathedral, while Muddy Creek’s high-grade zone has expanded, yielding rock samples up to 128.5 g/t Au. The discovery of antimony, copper, and other critical minerals enhances the project’s overall value and positions Nova is one of the growing companies to invest in, as it is likely to benefit from U.S. government initiatives focused on securing domestic critical mineral supplies.
Despite fluctuating revenues and recent losses, Nova Minerals remains strategically positioned for long-term growth. The Estelle Project’s multi-mineral potential, combined with consistent exploration success, aligns with the rising demand for both gold and critical minerals, making Nova an attractive player in the resource development sector.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.